04471nam 2201129z- 450 991055711270332120210501(CKB)5400000000040919(oapen)https://directory.doabooks.org/handle/20.500.12854/69408(oapen)doab69408(EXLCZ)99540000000004091920202105d2020 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierFreshwater Algal ToxinsMonitoring and Toxicity ProfileBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20201 online resource (208 p.)3-03943-679-1 3-03943-680-5 Cyanobacterial abundance has increased disproportionately, and this trend is likely to continue in the coming decades. This increase not only has deleterious effects on ecosystem biodiversity but also adversely affects drinking water supplies, livestock watering, crop yields, aquaculture, etc. Thus, the proliferation of cyanobacterial blooms presents human and animal health risks due to the common production of potent toxins, cyanotoxins. Moreover, these risks are aggravated by the accumulation potential of cyanotoxins and their transference to the food chain. In spite of the worldwide increasing occurrence of cyanotoxins, they are still underestimated in regulations. However, risk management of cyanotoxins is only possible after a thorough risk evaluation, and for that purpose, toxicity and exposure data are required. Thus, occurrence and monitoring information is of key importance, and new data in relation to the conditions that favor cyanobacterial growth and cyanotoxin production are welcome in order to prevent their appearance. On the other hand, in regard to toxicity, there are still many data gaps to fill. This book compiles 10 research papers and a review, which provide valuable contributions on all these aspects and demonstrate the importance of cyanobacteria toxins research.Freshwater Algal Toxins Environmental economicsbicsscResearch & information: generalbicsscAddacanine intoxicationclimatecolitiscoloncomet assaycyanobacteriacyanotoxincyanotoxinsCyanotoxinscyanotoxins mixturecylindrospermopsindextran sulfate sodiumdrinking water qualityELISAenzyme-modified comet assayflow cytometrygenotoxicityGreat LakesHABhairhepatotoxicityin vivoinflammatory bowel diseaseLC-MS/MSLeprdb/J miceliquid chromatographyliquid chromatography coupled to tandem mass spectrometry (LC-MS/MS)Llaytalong-term monitoringmanagement strategiesmass spectrometryMC-LAmetalmicrocystinmicrocystin congenersmicrocystin-LRMicrocystin-LRMicrocystis aeruginosamicronucleusMMPBmodellingMozambiquemultivariate statisticsn/aNo Observed Adverse Effect LevelNon-alcoholic Fatty Liver DiseaseNostocnutrientsoxidative stressplant growthPP2A inhibitionpublic healthratsraw water intakerisk assessmentstructureTiO2 enriched phosphopeptidestoxin bioaccumulationurinalysiszincEnvironmental economicsResearch & information: generalCameán Ana Medt0Jos AngelesedtCameán Ana MothJos AngelesothBOOK9910557112703321Freshwater Algal Toxins3036372UNINA04466nam 2201201z- 450 991056646220332120220506(CKB)5680000000037759(oapen)https://directory.doabooks.org/handle/20.500.12854/81172(oapen)doab81172(EXLCZ)99568000000003775920202205d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierOncolytic Virus ImmunotherapyBaselMDPI - Multidisciplinary Digital Publishing Institute20221 online resource (366 p.)3-0365-2549-1 3-0365-2548-3 Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, "Oncolytic Virus Immunotherapy", summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities.Clinical and internal medicinebicsscMedicine and Nursingbicsscadenovirusadoptive T cell therapyantigen-agnostic vaccinationantitumor immune responsearmingbiomarkerscancercancer immune therapycancer immunotherapycancer therapyCAR T cellcheckpoint inhibitorcheckpoint inhibitorsclass I HLAclinical trialscolorectal cancercombination therapycombinatory therapyCTLA-4deliveryDNA methyltransferase inhibitor (DNMTi)epigenetic silencinggenetic modificationglioblastomaHER2herpes simplex virusHSV-1immune checkpoint blockadeimmune checkpoint inhibitorimmunoeditingimmunogenic cell deathimmunostimulatoryimmunosurveillanceimmunotherapymeasles virusmelanomamulti-stagen/aNDVnewcastle disease virusoncogenic signalingoncolyticoncolytic adenovirusoncolytic virusoncolytic virusespancreatic cancerpancreatic ductal adenocarcinomaparvovirusPD-1PD-L1personalized oncolyticvirotherapyRASreovirusretargeted virussmall moleculetargetingtropism retargetingtumortumor microenvironmenttype I interferonvaccinationvector engineeringvesicular stomatitis virusviral mimicryvirotherapyαvβ6 integrinClinical and internal medicineMedicine and NursingMarchini Antonioedt1309617Ilkow Carolina SedtMelcher AlanedtMarchini AntonioothIlkow Carolina SothMelcher AlanothBOOK9910566462203321Oncolytic Virus Immunotherapy3029458UNINA